Advertisement

Topics

ImmusanT Raises $40 Million in Series C Financing

09:00 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-- ARCH Venture Partners joins Vatera Healthcare Partners as Equity Investor -- -- Proceeds Will Support Phase II Study of Nexvax2®, ImmusanT’s Immunotherapy and Diagnostic for Celiac Disease -- -- St...

Other Sources for this Article

ImmusanT Contact:
Leslie Williams, 617-299-8399 Ext. 201
President and CEO
Leslie@ImmusanT.com
or
Media Contact:
MacDougall Biomedical Communications
George E. MacDougall, 781-235-3093
george@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "ImmusanT Raises $40 Million in Series C Financing"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...